All In Biotech

Drug Trial Radar · NCT05584631

IVIG vs SCIG in CIDP

The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration

Last checked: Nov 20, 2026Latest source record: Dec 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Sep 11, 2022

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Rutgers, The State University of New JerseyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 18, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

Conditions

  • CIDP
  • Immunoglobulin Deficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy

Interventions

  • Intravenous immune globulin GDrug

    Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.

  • Subcutaneous immune globulin GDrug

    Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of drug half-lifeTime frame: Through study completion, an average of 4 weeks
  2. Assessment of immune globulin G serum concentration after intravenous immune globulin G administrationTime frame: Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
  3. Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administrationTime frame: Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rutgers, The State University of New Jersey Clinical Research Center

    New Brunswick, New Jersey · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.